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ABSTRACT. The reaction of cyclohexan-1,3-dione (1) with ethyl orthoformate (2) in acetic acid gave the 2-
(ethoxymethylene)cyclohexane-1,3-dione (3). The latter compound was used for further heterocyclization 
reactions to give thiophene, pyrazole and pyran derivatives. The cytotoxicity of the newly synthesized compound 
against the six cancer cell lines NUGC, DLDI, HA22T, HEPG2, HONE1 and MCF showed that compounds 5, 
10c, 10d, 13b, 14a, 18b, 18d, 18e and 20b were the most potent compounds. On the other hand, the toxicity of 
these compounds against shrimp larvae indicated that compounds 7a, 10c, 13b, 14a, 18b and 18d were non toxic 
against the tested organisms. Inhibition of the most potent compounds towards the tyrosine kinases c-kit, FIT-3, 
Vascular Endothelial Growth Factor Receptor (VEGFR)-2, Estimated Glomerular Filtration Rate (EGFR) and 
Platelet-Derived Growth Factor Receptor (PDGFR) revealed that compounds 5, 10c, 10d, 13b, 18b, 18d, 18e and 
20b were of the highest inhibitory effect. The Pim-1 kinase test revealed that compounds 10d, 18b and 20b were 
of the highest inhibitory effect. In addition, the c-Met enzymatic activities showed that compounds 10c, 10d, 18b, 
18e, 19 and 20b showed higher potencies against c-Met kinase than the reference foretinib. On the other hand, 
compounds 7a, 7b, 10d, 13a, 13b, 14a, 14b, 16a, 16b, 17, 18a-f, 19 and 20 showed higher inhibition towards PC-
3 cell line than the reference SGI-1776. Compounds 10c and 18b were of common potencies and their molecular 
docking was described. 
  




Major progress in cancer chemotherapy requires new drugs to eradicate the entire neoplastic 
diseases in human being. Finding a novel structure leads that may be of use in designing new, 
potent, selective, and less toxic anticancer agents remains a major challenge for medicinal 
chemistry researchers [1-4].  Random screening of natural products and synthetics has been the 
source of new leads in approaches to drug discovery [5-7]. In our ongoing search for the new 
potential antitumor agents, we therefore aimed to develop a series of new synthetic leads which 
are more accessible and more amenable to optimization through analog synthesis.  
Many planar heteroaromatic derivatives have shown anti-proliferative activity in vitro and 
some of them are important anticancer drugs [8-10]. Some of these types of compounds have the 
indazole nucleus which is a structural component of a large number of biologically active 
natural and unnatural compounds. Recently the high anti-proliferative activity of nitrogen 
containing heterocycles in two human breast cancer cell lines (MDAMB 231 and MCF-7) was 
reported and the authors were able to show that the tubulin is the primary target of these agents 
inhibiting its polymerization [11-13]. In the previous state of the art literature, the heterocycles 
containing sulfur and nitrogen possess a broad range of pharmaceutical activities. The family of 
sulfur heterocycles includes highly stable aromatic compounds that display physicochemical 
properties with relevance in the design of new materials, especially those relating to cancer 
treatments [14].  Among the sulfur heterocycles, benzo[b]thiophene is a unique heterocyclic core 
that has been picturized as an important pharmacophore of some bioactive molecules and 
therefore fascinated much interest [15, 16]. Thiophene containing compounds are well known to 
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exhibit various biological activities such as BACE1 inhibitors [17] and anti-breast cancer [18].  
Conversely, pyrazole derivatives have been reported in the literature to demonstrate anti-tumor 
[19] and kinase inhibitions [20].  Motivated by these results and in continuation of our previous 
work aimed at the synthesis of a new heterocyclic systems for anti-tumor evaluations [21-23]   
we report here the modification of cyclohexan-1,3-dione into a variety of novel condensed 
pyrazole, thiophene and isoxazole derivatives incorporating the cyclohexane moiety. It is relied 
on combination of different pharmacophores of bioactive compounds [24-27] to obtain new 
compounds with potent activity, increased selectivity and reduced adverse effects. Following 
this strategy and in a continuation of our previous study, we synthesized heterocyclic derivatives 
in most of the work using hydrazine and/or cyano derivatives [28-30] with cyclohexane-1,3-
dione aiming to synthesis heterocyclic scaffolds in order cumulate all the expected activities of 
the individual rings onto one structure. The anti-tumor evaluations followed by tyrosine kinase, 
Pim-1 kinases and c-Met inhibitions were measured for the newly synthesized target molecules.  
Additionally the confirmation of the structure of the newly synthesized compounds using 
different spectroscopic tools was described.  
RESULTS AND DISCUSSION 
 
In the present work, we are presenting the uses of cyclohexane-1,3-dione for the synthesis of 
pyrazole, thiophene, isoxazole and pyran derivatives using simple reaction sequences followed 
by the evaluation of the newly synthesized products against cancer cell lines and some kinases 
inhibitions. Thus, the reaction of cyclohexane-1,3-dione (1) with ethyl orthoformate (2) in acetic 
acid gave the 2-(ethoxymethylene)cyclohexane-1,3-dione (3) [31]. The structure of the latter 
product was based on its analytical and spectral data. The 1H NMR spectrum revealed, beside 
the expected signals, a triplet at  1.28 ppm indicating the presence of the CH3, a quartet at  
3.89 ppm for the CH2 group and a singlet at  6.79 ppm due to the presence of the CH group. 
Moreover, the 13C NMR spectrum showed the presence of  at 16.3 due to the presence of the 
OCH2CH3 group,  62.8 indicating the presence of the OCH2CH3 group, two signals at 112.3, 
158.2 due to the C=CH group and two signals at  177.3, 179.2 indicating the presence of the 
two CO groups. Compound 3 with the two active centers, the C=O group and the ethoxymethino 
moiety showed an interesting reactivity toward hydrazine hydrate. Thus, compound 3 reacted 
with hydrazine hydrate to give the 4-hydrazono-4,5,6,7-tetrahydro-2H-indazole (5) which was 
identified on the basis of its analytical and spectral data (see Experimental). The reaction of 
compound 3 with either of malononitrile (6a) or ethyl cyanoacetate (6b) gave the alkylated 
products 7a and 7b, respectively. Compounds 7a and 7b with different active sits towards 
nucleophilic reagents encourage us for their reactions with two folds of either of hydrazine 
hydrate (4) or phenylhydrazine (8) affording the 5-hydrazono-5,6,7,8-tetrahydro-2-substituted-
pyrazolo[3,4-b]quinoline derivatives 10a-d, respectively (Scheme 1). Formation of 10a-d 
occurred via the intermediacy of 9a-d followed by cyclization. The structures of 10a-d were 
established on the basis of their respective analytical and spectral data (see Experimental). 
Moreover, the reaction of either of compound 7a or 7b with hydroxylamine hydrochloride (11) 
gave the isoxazolo[3,4-b]quinolin-5(6H)-one oxime derivatives 13a and 13b, respectively 
through the intermediacy of 12a,b. The analytical and spectral data were consistent with their 
respective structures.  
 Next, we studied the Gewald's thiophene [32-34] synthesis using cyclohexane-1,3-dione (1). 
Thus, the reaction of compound 1 with either of malononitrile (6a) or ethyl cyanoacetate (6b) 
gave the thiophene derivatives 14a and 14b, respectively. 
 The reaction of either of compound 14a or 14b with cyanoacetylhydrazine (15) gave the 
hydrazide-hydrazone derivatives 16a and 16b, respectively (Scheme 2). The structures of 
compounds 16a and 16b were based on their respective analytical and spectral data. Thus, the 
1H NMR spectrum of 16a revealed the presence of a singlet at  4.42 ppm for the CH2 group of 
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the cyanoacetamido moiety, a singlet at  8.31 ppm (D2O exchangeable) indicating the presence 
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Scheme 1. Synthesis of compounds 3; 5; 7a,b and 10a-d. 
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Scheme 2. Synthesis of compounds 13a,b; 14a,b; 16a,d and 17. 
 
to the cyanoacetamido CH2 group, the presence of the two CN groups at  116.6, 117.4 and two 
signals at  164.8, 172.3 equivalent to the C=O and C=N groups, respectively. Further 
elucidation for the structures of compounds 16a and 16b was obtained through their synthesis 
via another reaction route. Thus, the reaction of molar ratio cyclohexane-1,3-dione (1) and 
cyanoacetylhydrazine (15) gave the hydrazide-hydrazone derivative 17. The latter compound 
reacted with either of malononitrile (2a) or ethyl cyanoacetate (2b) and elemental sulfur to give 
the same thiophene derivatives 16a and 16b, respectively (m.p., mixed m.p. and finger print IR 
spectra). 
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It is well known that multi-component reactions (MCRs) can combine three or more 
components together in a single reaction vessel and produce final products with a minimum of 
synthetic time and effort [35] because they are no need to separate any reaction intermediate 
[36]. Such MCRs often result in high atom economy and high selectivity products [37]. They 
are also applicable to the synthesis of heterocyclic systems [38]. It is quite remarkable that many 
top-selling pharmaceuticals contains 4-H pyran derivatives [39-43] this encouraged us to 
synthesis 4-H pyran derivatives through the multi-component reactions of compounds 14a,b. 
Therefore, the reaction of either of compound 14a or 14b with any of the aromatic aldehydes 7a, 
7b or 7c and malononitrile (2a) gave the 5,6-dihydro-4H-thieno[3,2-h]chromen-8-amine 
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Scheme 3. Synthesis of compounds 19a-f; 19 and 20a,b. 
  
 The two amino groups in compounds 18a-f were of different nucleophilicity. The amino 
group located at C-2 close to the aromatic thiophene moiety showed more nucleophilicity than 
the amino group at C-8 close the pyran moiety. It is noteworthy that the amino group in the 8-
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aminopyran moiety possesses much lower nucleophilicity compared to aliphatic amines due to 
its lower location at the C-2 carbon bonded to the oxygen [44] such amino group usually 
requires a catalytic base to initiate its nucleophilicty [45]. Thus, throughout our work, the 
reaction of compound 18a, as a derivative of 18a-f, with ethyl cyanoacetate (2a) without the use 
any catalyst in dimethylformamide under reflux gave the 2-cyanoacetamido derivative 19. 
Compound 16a was capable for further thiophene synthesis, due the presence of the 
cyanomethlene moiety, through its reaction with either of malononitrile (2a) or ethyl 
cyanoacetate (2b) and elemental sulfur to give the 5-amino-3-cyanothiophene-2-carboxamide 
derivatives 20a and 20b, respectively (Scheme 3).  
 
In vitro cytotoxic assay  
 
Table 1. Cytotoxicity of novel compounds against a variety of cancer cell linesa [IC50
b (nM)]. 
                                                  
Compound Cytotoxocity (IC50 in nM) 
 NUGC DLDI HA22T HEPG2 HONE1 MCF WI38 
3   2160 3210 2765 1541 1220 2659 na 
5   42 68 584 228 167 268 na 
7a   420 428 325 118 529 168 na 
7b   2138 2279 1340 250 1549 1618 na 
10a   1242 2360 2157 3212 1287 2130 na 
10b   1107 2150 2148 2138 1268 2190 na 
10c   124 121 38 155 178 420 na 
10d   120 58 210 320 79 154 na 
13a   1280 2360 3268 3385 2428 2530 na 
13b   66 222 1124 217 2254 2128 na 
14a   88 650 463 160 318 130 na 
14b   1870 990 2158 1380 2442 1639 na 
16a   1150 408 1319 2170 2048 1149 868 
16b   1035 3160 2088 2116 2180 1274 na 
17   1238 2254 2237 2429 1179 2480 na 
18a   1335 3280 2016 1380 4270 3240 na 
18b   314 155 128 70 69 154 na 
18c   1128 273 168 528 318 80 na 
18d   84 1490 2168 1299 2034 2868 na 
18e   118 219 364 306 260 1055 na 
18f   1282 1290 2369 1046 1077 2362 na 
19   1028 2428 2118 1090 1428 2248 na 
20a   1072 1169 2529 1165 550 280 na 
20b   128 270 56 1068 148 440 na 
Foretinib     23 258 48 240 35 63 na 
aNUGC, gastric cancer, DLDI, colon cancer, HA22T, liver cancer, HEPG2, liver cancer; HONEI, nasopharyngeal 
carcinoma; HR, gastric cancer; MCF, breast cancer; WI38, normal fibroblast cells. bThe sample concentration 
produces a 50% reduction in cell growth. na = not active. 
 
Structure activity relationship 
 
It is clear from Table 1 that the cytotoxicity of the newly synthesized products against NUGC, 
DLDI, HA22T, HEPG2, HONE1 and MCF using foretinib as the reference showed that 
compounds 5, 7a, 10c, 10d, 13b, 14a, 18b, 18d, 18e and 20b were the most cytotoxic 
compounds among the tested compounds. The 2-(ethoxymethylene)cyclohexane-1,3-dione (3) 
showed very low cytotoxicity towards the six cancer cell lines, however, its reaction with 
hydrazine hydrate to give the 4-hydrazono-4,5,6,7-tetrahydro-2H-indazole derivative 5 which is 
the nitrogen rich compound with high cytotoxicity towards the six cancer cell lines. It is of great 
Synthesis of new thiophene, pyrazole, isoxazole derivatives  
Bull. Chem. Soc. Ethiop. 2018, 32(2) 
291
value to note that compound 5 showed higher cytotoxicity againt HEPG2 cell line than foretinib 
with IC50 228 nM. It is clear that the fused pyrazole derivative 5 showed higher cytotoxicity than 
the 2-(ethoxymethylene)cyclohexane-1,3-dione (3). On the other hand, the reaction of 
compound 3 with either of malononitrile or ethyl cyanoacetate gave compounds 7a and 7b with 
different potencies. Thus, it is obvious that compound 7a with the dicyano moieties showed 
remarkable cytotoxicity higher than 7b towards the six cancer cell lines, although compound 7b 
showed high potency against HEPG2 cell line with IC50 250 nM by a value that very close to 
that foretinib. Considering, nitrogen rich compounds, the 5,6,7,8-tetrahydro-pyrazolo[3,4-
b]quinoline derivatives 10a-d, it is clear that compounds 10c (Y = OH, R’ = H) and 10d (Y = 
OH, R’ = Ph) showed the highest cytotoxicity among the four compounds. The high potencies 
of compounds 10c and 10d were attributed to the presence of the OH group in these compounds. 
Compound 10d showed a higher cytotxiciy than foretinib towards DLDI with IC50 58 nM. In 
general compound 7a showed the highest cytotoxicity which is close that those of the tricyclic 
compounds 10c and 10d. Reaction of either of compound 7a or 7b with hydroxylamine 
hydrochloride gave 5,6,7,8-tetrahydroisoxazolo[3,4-b]quinoline derivatives 13a  and 13b where 
compound 13b (Y =  OH) showed higher cytotoxicity than 13a towards the three cancer cell 
lines NUGC, DLDI, HEPG2  with IC50’s  66, 222, and 217 nM, respectively. It is obvious that 
tricyclic pyridinopyrazole derivatives 10c,d showed higher cytotoxicity toward the six cancer 
cell lines than the the tricyclic pyridinoisoxazole derivative 13b as the latter showed low 
potency against HONE1 and MCF cell lines.  
Considering the thiophene derivatives 14a,b it is clear that compound 14a (R = CN) showed 
higher cytotoxicity against the six cancer cell lines than compound 14b. The reactivity of 14a 
was attributed to the presence of the electronegative CN group. For the hydrazide-hydrazone 
derivatives 16a and 16b it is obvious that compound 16a (R = CN) showed high cytotoxicity 
only towards DLDI cell line with IC50 408 nM while compound 16b (R = COOEt) showed low 
potencies against the six cancer cell lines. On the other hand, both of the hydrazidehydrazone 
derivative 17 showed low potencies towards the six cancer cell lines. Comparison of the 
thiophene derivatives 14a,b, the hydrazide-hydraone derivatives 16a,b and 17 revealed that the 
thiophene derivative 14a with the highest cytotoxicity among the five compounds. 
Considering the multi-component products the thieno[3,2-h]chromene-3-carbonitrile 
derivatives 18a-f, it is clear that compounds 18b (R = CN, Y = Cl) and 18c (R = CN, Y = 
OCH3) showed the highest cytotoxicity among the six compounds. On the other hand, 
compound 18d (R = COOEt, Y = H) showed high cytotoxicity against NUGC cell line with IC50 
84 nM but compound 18e (R = COOEt, Y = Cl) revealed high cytotoxicity against the five 
cancer cell lines NUGC, DLDI, HA22T, HEPG2 and HONE1. It is obvious through compounds 
18a-f that the presence of either the CN or Cl groups enhances the high potencies of compounds 
18b and 18c. The thieno[3,2-h]chromen-8-yl)-2-cyanoacetamide derivative 19 exhibited low 
potency towards the six cancer cell lines. It is clear that the cyanoacetamido moiety reduce the 
potency of compound 19. It is obvious that compounds 18b,d,e showed the highest cytotoxicity 
among the pyran derivatives 18a-d and 19. Considering the dihydrobenzo[b]thiophen-7(4H)-
ylidene)thiophene-2-carbohydrazide derivatives 20a,b with the two thieno moieties showed 
activities towards some selective cell lines. Thus, compound 20a (R = CN) showed high 
potency against HONE1 and MCF cell lines while 20b (R = COOEt) showed high potency 
towards all the cancer cell lines except with HEPG2 that showed low potency. In addition, 
compound 20b showed cytotoxicity against HA22T cell line very close to that of foretinib with 
IC50 56 nM. The cytotoxicity evaluation of the synthesized compounds toward the six cancer 
cell lines are illustrated through Figure 1.  
Toxicity  
Bioactive compounds are often toxic to shrimp larvae. Thus, in order to monitor these chemicals 
in vivo lethality to shrimp larvae (Artemiasalina), Brine-Shrimp Lethality Assay [46] was used. 
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Results were analyzed with LC50 program to determine LC50 values and 95% confidence 
intervals [47]. Results are given in Table 2 the following ten compounds 5, 7a, 10c, 10d, 13b, 
14a, 18b, 18d, 18e and 20b which exhibited optimal cytotoxic effect against cancer cell lines. 
The shrimp lethality assay was considered as a useful tool for preliminary assessment of 
toxicity, and it has been used for the detection of fungal toxins, plant extract toxicity, heavy 
metals, cyanobacteria toxins, pesticides, and cytotoxicity testing of dental materials [48] natural 
and synthetic organic compounds [49].  It has also been shown that A. salina toxicity test results 
have a correlation with rodent and human acute oral toxicity data. Generally, a good correlation 
was obtained between A. salina toxicity test and the rodent data. Likewise, the predictive 
screening potential of the aquatic invertebrate tests for acute oral toxicity in man, including A. 
























































NUGC DLDI HA22T HEPG2 HONE1 MCF
Synthesis of new thiophene, pyrazole, isoxazole derivatives  
Bull. Chem. Soc. Ethiop. 2018, 32(2) 
293
  In order to prevent the toxicity results from possible false effects originated from solubility 
of compounds and dimethyl-sulfoxide DMSO’s possible toxicity effect, solutions of the test 
compounds were prepared in the suggested dimethyl-sulfoxide (DMSO) volume ranges. It is 
clear from Table 2 that compounds 7a, 10c, 13b, 14a, 18b and 18d were non toxic against the 
tested organisms. While compound 10d was very toxic and that compounds 5, 18e and 20a were 
harmful towards the tested organisms.  
 


















































































Harmful 340 89.5 60.2 
aTen organisms (A. salina) tested for each concentration. 
 
HTRF kinase assay 
 
We studied the activity of the synthesized compounds towards PC-3 prostate cancer cell line, 
results are demonstrated through Table 3. The c-Met kinase activity of all compounds was 
evaluated using homogeneous time-resolved fluorescence (HTRF) assay as previously reported 
[50, 51]. Briefly, 20 µg/mL poly (Glu, Tyr) 4:1 (Sigma) was pre-coated as a substrate in 384-
well plates. Then 50 mL of 10 mM ATP (Invitrogen) solution diluted in kinase reaction buffer 
(50 mM HEPES, Ph 7.0, 1 M DTT, 1 M MgCl2, 1 M MnCl2, and 0.1% NaN3) was added to each 
well. Various concentrations of compounds diluted in 10 mL of 1% DMSO (v/v) were used as 
the negative control. The kinase reaction was initiated by the addition of purified tyrosine kinase 
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proteins diluted in 39 mL of kinase reaction buffer solution. The incubation time for the 
reactions was 30 min at 25 oC and stopped by the addition of 5 mL of Streptavidin-XL665 and 5 
L Tk Antibody Cryptate working solution to all of wells. The plates were read using Envision 
(PerkinElmer) at 320 and 615 nM. The inhibition rate (%) was calculated using the following 
equation: % inhibition = 100 - [(Activity of enzyme with tested compounds - Min)/(Max  - 
Min)] x 100 (Max: the observed enzyme activity measured in the presence of enzyme, 
substrates, and cofactors; Min: the observed enzyme activity in the presence of substrates, 
cofactors and in the absence of enzyme). IC50 values were calculated from the inhibition curves. 
 
In vitro enzymatic assays 
 
All newly synthesized thiophene derivatives were evaluated for their inhibitory activity toward 
c-Met enzyme using a homogeneous time-resolved fluorescence (HTRF) assay. Taking foretinib 
as the positive control, the results expressed as IC50 were summarized in Table 1. The IC50 
values are the average of at least three independent experiments. As illustrated in Table 1, all the 
tested compounds displayed potent c-Met enzymatic activity with IC50 values ranging from 0.29 
to 12.25  nM, compared with foretinib (IC50 = 1.16 nM). 
 









3 - - - 12.25± 6.17 8.29± 4.62 
5  - - - 8.42 ± 3.05 0.93 ± 0.20 
7a - CN - 1.38 ± 0.84 0.42 ± 0.16 
7b - COOEt - 1.06 ± 0.37 0.63 ± 0.25 
10a NH2 - H 2.46± 0.81 6.75± 1.26 
10b NH2 - Ph 8.84 ±4.58 9.36 ±4.27 
10c OH - H 0.39 ± 0.14 4.26 ± 1.29 
10d OH - Ph 0.92± 0.28 1.15 ±0.62 
13a NH2 - - 8.15 ±2.03 0.46 ±0.17 
13b OH - - 1.28 ± 0.51 0.16 ± 0.02 
14a - CN - 3.06±1.17 0.31 ±0.05 
14b - COOEt - 1.23 ±0.72 0.90 ± 0.23 
16a - CN - 1.23 ±2.55 0.63 ±0.19 
16b - COOEt - 1.21 ±0.61 0.12 ±0.21 
17 - - - 5.32 ±1.52 3.42 ±1.29 
18a H CN - 4.56 ±1.29 3.18 ±1.27 
18b Cl CN - 0.29±0.08 0.09± 0.002 
18c OCH3 CN - 2.42±1.39 0.29 ±0.05 
18d H COOEt - 3.26 ±1.42 1.35± 0.58 
18e Cl COOEt - 0.64 ±0.21 0.28±0.09 
18f OCH3 COOEt - 5.43 ± 1.16 2.29 ± 0.85 
19 - - - 0.43 ± 0.28 0.22 ± 0.06 
20a - CN - 4.19 ±1.34 8.58 ± 2.41 
20b - COOEt - 1.05 ±0.59 1.25± 0.46 
 - - - Foretinib  
1.16 ± 0.17 
SGI-1776 
4.86 ± 0.16 
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It is clear from Table 3 that compounds 3 and 5 showed low inhibition toward c-Met but 
compound 5 showed high inhibition toward the prostate cancer cell line PC-3. On the other hand 
compounds 7a and 7b showed high inhibitions toward c-Met kinase and PC-3 cell line. 
Considering the 5,6,7,8-tetrahydro-pyrazolo[3,4-b]quinoline derivatives 10a-d, it is clear that 
compounds 10c (Y = OH) and 10d (Y = OH , R' = Ph) showed the highest inhibition toward     
c-Met kinase among the four compounds. While compound 10d showed high cytotoxicity 
toward PC-3 cell line with IC50 1.15 nM. Considering the 5,6,7,8-tetrahydroisoxazolo[3,4-
b]quinoline derivatives 13a  and 13b where compound 13b (Y = OH) revealed higher inhibition 
toward c-Met kinase than compound 13a (Y = NH2). However both of 13a and 13b showed 
high inhibition toward PC-3 cell line with IC50's 0.46 and 0.16 nM, respectively. The thiophene 
derivative 14a (X = CN) showed high inhibition towards PC-3 cell line with IC50 0.31 nM and it 
gave moderate potency against c-Met kinase but the thiophene derivative 14b (X = COOEt) 
gave high potencies against both of c-Met kinase and PC-3 cell line. For the hydrazide-
hydrazone derivatives 16a and 16b it is obvious that both of then showed high potencies against 
c-Met kinase and PC-3 cell line. Compound 17 showed low potencies against c-Met kinase and 
PC-3 cell line. For compounds 18a-f, it is clear that compounds 18b (X = Cl, R = CN) and 18e 
(X = Cl, R = COOEt) showed high inhibition toward c-Met kinase and PC-3 cell line. The 2-
cyanoacetamide derivative 19 showed high potencies c-Met kinase and PC-3 cell line with IC50's 
0.43 and 0.22 nM, respectively. Considering the dihydrobenzo[b]thiophen-7(4H)-ylidene)- 
thiophene-2-carbohydrazide derivatives 20a,b it is evident that compound 20b showed highest 
potencies c-Met kinase and PC-3 cell line. Among the tested compounds it is clear from Table 3 
that compounds 10c, 10d, 18b, 18e, 19 and 20b showed higher potencies against c-Met kinase 
than the reference foretinib. While compounds 7a,7b, 10d, 13a, 13b, 14a, 14b, 16a, 16b, 17, 
18a-f, 19 and 20 showed higher inhibition towards PC-3 cell line than the reference SGI-1776. 
 
Table 4. Inhibition of tyrosine kinases (Enzyme IC50 (nM) for compounds 5, 7a, 10c, 10d, 13b, 14a, 18b, 
18d, 18e, 20a and 20b. 
 
Compound c-Kit Flt-3 VEGFR-2 EGFR PDGFR 
5 1.23 1.08 0.98 2.41 1.62 
7a 8.27 10.40 8.59 10.28 8.63 
10c 1.09 1.21 1.47 0.68 2.30 
10d 0.24 0.25 0.29 0.51 0.32 
13b 1.26 1.01 0.73 1.18 0.62 
14a 10.21 9.32 8.07 7.59 9.23 
18b 1.35 1.59 0.83 0.37 1.25 
18d 0.37 0.69 0.42 0.29 0.41 
18e 1.40 1.52 1.61 0.26 0.80 
20a 5.27 6.21 8.39 4.18 7.33 
20b 0.34 0.26 0.41 0.64 1.38 
Foretinib 0.19 0.17 0.20 0.13 0.26 
 
Inhibition of selected compounds against tyrosine kinases 
 
The most potent compounds toward the cancer cell lines 5, 7a, 10c, 10d, 13b, 14a, 18b, 18d, 
18e, 20a and 20b were further investigated towards the five tyrosine kinases c-kit, FIT-3, 
VEGFR-2, EGFR and PDGFR and the data were expressed through Table 4. It is clear that 
compounds 5, 10c, 10d, 13b, 18b, 18d, 18e and 20b showed the highest inhibitory effect while 
compounds 7a, 14a and 20a showed the least inhibition. It is of great value to note that 
compounds 10d, 18d and 20b exhibit the maximum inhibitory effect among the eleven tested 
compounds. Specifically, the 5-hydrazono-5,6,7,8-tetrahydro-2H-pyrazolo[3,4-b]quinoline 
derivative 10c (Y = OH, R = H) showed the highest activity toward EGFR kinase with IC50 0.68 
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nM, while the 3-hydroxy-7,8-dihydroisoxazolo[3,4-b]quinolin-5(6H)-one oxime (13b) (Y  = 
OH) gave the highest inhibition towards VEGFR-2 and PDGFR kinase with IC50's 0.73 and 0.62 
nM, respectively. Compound 18e (Y = OCH3, R = CN) showed its highest inhibition against 
EGFR and PDGFR kinases with IC50’s 0.26 and 0.80 nM. 
 
Inhibition of Pim-1 kinase for compounds 10d, 13b, 18b, 18d and 20b 
 
Although they are frequently implicated in acute myeloid leukemia (AML) [52] Pim kinases are 
over expressed in many other types of hematological malignancies and solid tumors. 
Specifically, over expression has been identified in bladder [53], prostate [54], and head and 
neck cancers [55], chronic lymphocytic leukemia [56], multiple myeloma [57] and other B cell 
malignancies [58]. Over expression of Pim kinases was often associated with poor prognosis in 
each of these cancers. This relation between the Pim-1 kinase and cancer encouraged us to study 
the Pim-1 kinase of some compounds. Thus, the five compounds 10d, 13b, 18b, 18d and 20b 
were selected for testing of their inhibition for the Pim-1 kinase (Table 5) due to their anti-
proliferation activities against the cancer cell lines and their high activities against c-Met kinase. 
The study showed that compounds 10d (Y = OH, R = Ph), 18b (Y = Cl, R = CN) and 20b (R = 
COOEt) showed IC50’s 0.28, 0.63 and 0.59 M, respectively. While compounds 13b (Y = OH) 
and 18d (Y = H, R = COOEt) showed no activities.  
 
Table 5. Inhibition of Pim-1 kinase for compounds 10d, 13b, 18b, 18d and 20b. 
 
Compound Inhibition ratio at 10 M IC50 (M) 
10d 94 0.28      
13b 28 > 10 
18b 84 0.63 
18d 36 >10 
20b 88 0.59 
SGI-1776 - 0.048 
 
It is important to note that throughout the biology sections that we used two different 
references, foretinib was used for the cytotoxicity of compounds and c-Met enzymatic inhibition 
while SGI-1776 was used for Pim-1 inhibition [59].  
In summary, 10c and 18b were the most potent compounds beside their non toxicity against 
shrimp larvae and high inhibition against c-Met kinase. The in vivo activity estimate of 
compounds 10c and 18b represent an integration of different factors and to find differences 
between in vitro and in vivo responses elucidated by these compounds is hardly surprising.  For 
that reason molecular modeling of compounds 10c and 18b was carried out and the results 
showed that these two compounds were close to foretinib concerning the - interaction and the 
binding energy score. 
 
Table 6. Docking study data showing amino acid interactions and the hydrogren bond lengths of target 
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Throughout this work the cyclohexane-1,3-dione was used for the synthesis of thiophene, 
pyrazole and pyran derivatives. The anti-tumor evaluation of the newly synthesized compounds 
against the six cancer cell NUGC, DLDI, HA22T, HEPG2, HONE1 and MCF showed that 
compounds 10c and 18b were the most potent compounds beside their non toxicity against 
shrimp larvae and high inhibition against c-Met kinase. The Pim-1 kinase test indicated that 
compounds 10d, 18b and 20b were the most inhibitory compounds. It can be suggested that the 
inclusion of aromatic rings in the structure of the compound improves the cytotoxic activity of 
this class of compounds in addition, the presence of halogens, hydroxyl or cyano groups directly 






Fetal bovine serum (FBS) and L-glutamine were purchased from Gibco Invitrogen Co. 
(Scotland, UK). RPMI-1640 medium was purchased from Cambrex (New Jersey, USA). 
Dimethyl-sulfoxide (DMSO), doxorubicin, penicillin, streptomycin and sulforhodamine B 




Cell cultures were obtained from the European Collection of cell Cultures (ECACC, Salisbury, 
UK) and human gastric cancer (NUGC and HR), human colon cancer (DLD1), human liver 
cancer (HA22T and HEPG2), human breast cancer (MCF), nasopharyngeal carcinoma 
(HONE1) and normal fibroblast cells (WI38) were kindly provided by the National Cancer 
Institute (NCI, Cairo, Egypt). They grow as monolayer and routinely maintained in RPMI-1640 
medium supplemented with 5% heat inactivated FBS, 2 M glutamine and antibiotics (penicillin 
100 U/mL, streptomycin 100 µg/mL), at 37 oC in a humidified atmosphere containing 5% CO2. 
Exponentially growing cells were obtained by plating 1.5 x 105 cells/mL for the seven human 
cancer cell lines including cells derived from 0.75 x 104 cells/mL followed by 24 h of 
incubation. The effect of the vehicle solvent DMSO on the growth of these cell lines was 
evaluated in all the experiments by exposing untreated control cells to the maximum 
concentration (0.5%) of DMSO used in each assay. 
The heterocyclic compounds, prepared in this study, were evaluated according to standard 
protocols for their in vitro cytotoxicity against seven human cancer cell lines including cells 
derived from human gastric cancer (NUGC and HR), human colon cancer (DLD1), human liver 
cancer (HA22T and HEPG2), human breast cancer (MCF), nasopharyngeal carcinoma 
(HONE1) and normal fibroblast cells (WI38). All of IC50 values are listed in Table 1 using 
foretinib as the reference compound. Some heterocyclic compounds was observed with 
significant cytotoxicity against most of the cancer cell lines tested (IC50 = 10–1000 nM). Normal 
fibroblasts cells (WI38) were affected to a much lesser extent (IC50 > 10,000 nM). 
 
Procedure of HTRF kinase  
 
Briefly, 20 g/mL poly (Glu, Tyr) 4:1 (Sigma) was used as a substrate in 384-well plates. Then 
50 L of 10 mM ATP (Invitrogen) solution diluted in kinase reaction buffer (50 mM N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), Ph 7.0, 1 M dithiothreitol (DTT), 1 
M MgCl2, 1 M MnCl2, and 0.1% NaN3) was added to each well. Various concentrations of the 
tested compounds diluted in 10 L of 1% DMSO (v/v) were used as the negative control. The 
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kinase reaction was started by the addition of purified tyrosine kinase proteins diluted in 39 L 
of kinase reaction buffer solution. The incubation time for the reactions was 30 min at 25 oC and 
ceased by the addition of 5 L of Streptavidin-XL665 and 5 L Tk Antibody Cryptate working 
solution to all of wells. The plates were read using Envision (PerkinElmer) at 320 and 615 nM. 
The inhibition rate (%) was calculated using the mathematical equation: % inhibition = 100 - 
[(Activity of enzyme with tested compounds - Min)/(Max  - Min)]  x 100 (Max: the observed 
enzyme activity measured in the presence of enzyme, substrates, and cofactors; Min: the 
observed enzyme activity in the presence of substrates, cofactors and in the absence of enzyme). 
 
General   
 
All melting points were determined on an Electrothermal digital melting point apparatus and are 
uncorrected. IR spectra (KBr discs) were recorded on a FTIR plus 460 or Pye Unicam SP-1000 
spectrophotometer (Pye Unicam, UK, Cambridge). 1H NMR and 13C NMR spectra were 
recorded with Varian Gemini-200 (200 MHz, Varian UK) and JEOL AS 500 MHz (JEOL, 
Japan) instruments in DMSO-d6 as solvent, using Tetraethylsilane (TMS) as internal standard 
chemical shifts are expressed as δ ppm. The mass spectra were recorded with Hewlett Packard 
5988 A GC/MS system (Hewlett Packard, Agilent, USA) and GCMS-QP 1000Ex Shimadzu (EI, 
70 eV) (Shimadzu, Japan) instruments. Analytical data were obtained from on Vario EL III 
Elemental CHNS analyzer. Compound 3 was previously reported, although its characterization 
and spectral data were not presented [31].  
 
2-(Ethoxymethylene)cyclohexane-1,3-dione (3). To a solution of cyclohexan-1,3-dione (1.12 g, 
0.01 mol) in acetic acid (40 mL) ethyl orthoformate (1.68 g, 0.01 mol) was added. The reaction 
mixture was heated under reflux for 2 h then evaporated in vacuum and the remaining product 
was triturated with ethanol and the formed solid product was collected by filtration. Yellow 
crystals from ethanol, yield (1.27 g, 76%), mp 282-285 oC, IR (KBr) νmax cm
-1: 2980 (CH2), 
1689, 1686 (CO), 1632 (C=C); 1H NMR (DMSO-d6, 200 MHz): = 1.28 (t, 3H, CH3 ), 1.49-
1.67 (m, 2H, CH2), 2.65-2.73 (m, 4H, 2CH2), 3.89 (q, 2H, CH2), 6.79 (s, 1H, CH), 
13C NMR 
(DMSO-d6, 75 MHz): 16.3 (OCH2CH3), 16.2, 36.8, 39.0 (3CH2), 62.8 (OCH2CH3), 112.3, 
158.2 (C=CH), 177.3, 179.2 (2CO). EIMS:  m/z 168  [M]+  (26%); analysis calcd for C9H12O3 
(168.19): C, 64.27; H, 7.19%. Found: C, 64.08; H, 7.33%. 
 
4-Hydrazono-4,5,6,7-tetrahydro-2H-indazole (5). To a solution of compound 3 (1.68 g, 0.01 
mol), in ethanol (40 mL) hydrazine hydrate (0.10 g, 0.02 mol) was added. The reaction mixture 
was heated under reflux for 3 h then poured onto ice/water containing few drops of hydrochloric 
acid and the formed solid product was collected by filtration. Yellow crystals from ethanol, 
yield (1.15 g, 77%) mp > 300 oC, IR (KBr) νmax cm
-1: 3466-3329 (NH2, NH), 3487, 3342 (NH2, 
NH), 2987 (CH2), 1663, 1658 (two exocyclic C=N), 1630 (C=C); 
1H NMR (DMSO-d6, 200 
MHz): = 1.46-1.69 (m, 2H, CH2), 2.68-2.71 (m, 4H, 2CH2), 4.23 (s, br, 2H, D2O 
exchangeable, NH2), 5.63 (s, 1H, pyrazole H-5), 8.32 (s, 1H, D2O exchangeable, NH); 
13C NMR 
(DMSO-d6, 75 MHz): 18.6, 36.9, 39.6 (3CH2), 143.2, 146.8 (pyrazole C-4, C-5),  180.1, 182.6 
(2C=N). EIMS: m/z 150  [M]+ (38%); analysis calcd for C7H10N4 (150.18): C, 55.98; H, 6.71; N, 
37.31%. Found: C, 56.22; H, 6.89; N, 37.08%. 
 
General procedure for the synthesis of the cyclohexylidene)propanenitrile derivatives 7a,b    
 
To a solution of compound 3 (1.68 g, 0.01 mol) in 1,4-dioxane (40 mL) containing triethylamine 
(0.50 mL) either of malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.07, 0.01 mol) was 
added. The reaction mixture, in each case, was heated under reflux for 4 h then left to cool and 
the formed solid product was collected by filtration.  
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2-((2,6-Dioxocyclohexylidene)methyl)malononitrile (7a). Yellow crystals from ethanol, yield 
(1.46 g, 78%), mp 280-282  oC, IR (KBr) νmax cm
-1: 2984 (CH2), 2223, 2220 (2CN), 1689, 1686 
(CO), 1630 (C=C); 1H NMR (DMSO-d6, 200 MHz): = 1.46-1.69  (m, 2H, CH2), 2.65-2.70 (m, 
4H, 2CH2), 6.80, 7.03 (2d, 2H, CH-CH); 
13C NMR (DMSO-d6, 75 MHz): 18.9, 37.3, 39.4 
(3CH2), 82.3, 138.2 (CH-CH), 116.2, 116.9 (2CN), 129.8 (cyclohexane C-2), 167.8, 169.3 
(2C=O). EIMS: m/z 188 [M]+ (24%); analysis calcd for C10H8N2O2 (188.18): C, 63.82; H, 4.28; 
N, 14.89%. Found: C, 63.69; H, 4.08; N, 15.23%. 
 
Ethyl 2-cyano-3-(2,6-dioxocyclohexylidene)propanoate (7b). Yellow crystals from ethanol, 
yield (1.95 g, 83%), mp 262-264 oC. IR (KBr) νmax cm
-1: 2989 (CH2), 2220 (CN), 1690, 1688-
1686 (3CO), 1633 (C=C); 1H NMR (DMSO-d6, 200 MHz): = 1.13 (t, 3H, J =  7.23 Hz, CH3), 
1.43-1.67 (m, 2H, CH2), 2.64-2.72 (m, 4H, 2CH2), 4.20 (q, 2H, J =  7.23 Hz, CH2), 6.83, 7.01 
(2d, 2H, CH-CH); 13C NMR (DMSO-d6, 75 MHz): 16.3 (OCH2CH3), 18.6, 37.7, 39.8 (3CH2), 
56.4 (OCH2CH3), 82.6, 138.4 (CH-CH), 116.6 (CN), 129.6 (cyclohexane C-2), 164.2, 167.4, 
169.6 (3C=O). EIMS:  m/z 235  [M]+  (20%); analysis calcd for C12H13NO4 (235.24): C, 61.27; 
H, 5.57; N, 5.95%. Found: C, 61.38; H, 5.72; N, 6.21%. 
 
General procedure for the synthesis of the 5,6,7,8-tetrahydro-2H-pyrazolo[3,4-b]quinoline 
derivatives 10a-d 
 
To a solution either of compound 7a (1.88 g, 0.01 mol) or 7b (2.35 g, 0.01 mol) in 1,4-dioxane 
(40 mL) either of hydrazine hydrate (1.0 g, 0.02 mol) or phenylhydrazine (2.16 g, 0.02 mol) was 
added. The reaction mixture was heated under reflux for 4 h then poured onto ice/water 
containing few drops of hydrochloric acid and the formed solid product was collected by 
filtration. 
 
5-Hydrazono-5,6,7,8-tetrahydro-2H-pyrazolo[3,4-b]quinolin-3-amine (10a). Yellow crystals 
from ethanol, yield (1.64 g, 76%), mp 290-293 oC, IR (KBr) νmax cm
-1: 3488-3431 (2NH2, NH), 
2987 (CH2), 1650 (exocyclic C=N), 1631 (C=C); 
1H NMR (DMSO-d6, 200 MHz): = 1.40-1.69 
(m, 2H, CH2), 2.64-2.75 (m, 4H, 2CH2), 4.82, 5.14 (2s, 4H, D2O exchangeable, 2NH2), 6.80 (s, 
1H, pyridine H-4), 8.29 (s, 1H, D2O exchangeable, NH); 
13C NMR (DMSO-d6, 75 MHz): 
19.3, 29.3, 35.2 (3CH2), 119.2, 122.6, 124.9, 133.1 (pyrazole C-4, C-5, pyridine C-3, C-4),   
153.8, 156.9, 169.2 (3C=N). EIMS: m/z 216 [M]+ (18%); analysis calcd for C10H12N6 (216.24): 
C, 55.54; H, 5.59; N, 38.86%. Found: C, 55.69; H, 5.70; N, 38.92%. 
 
2-Phenyl-5-(2-phenylhydrazono)-5,6,7,8-tetrahydro-2H-pyrazolo[3,4-b]quinolin-3-amine (10b). 
Orange crystals from ethanol, yield (3.16 g, 86%), mp 233-236 oC, IR (KBr) νmax cm
-1: 3476-
3445 (NH2, NH), 2989 (CH2), 1654 (exocyclic C=N), 1633 (C=C); 
1H NMR (DMSO-d6, 200 
MHz): = 1.38-1.69 (m, 2H, CH2), 2.62-2.74 (m, 4H, 2CH2), 4.83 (s, 2H, D2O exchangeable, 
NH2), 6.82 (s, 1H, pyridine H-4), 7.28-7.38 (m, 10H, 2C6H5), 8.27 (s, 1H, D2O exchangeable, 
NH); 13C NMR (DMSO-d6, 75 MHz): 19.6, 29.5, 35.8 (3CH2), 119.6, 120.5, 122.4, 124.5, 
126.9, 127.4, 128.0, 129.0, 133.2, 133.7, 134.1 (2C6H5, pyrazole C-4, C-5, pyridine C-3, C-4), 
153.6, 158.3, 164.2 (3C=N). EIMS: m/z 368 [M]+ (22%); analysis calcd for C22H20N6 (368.43): 
C, 71.72; H, 5.47; N, 22.81%. Found: C, 71.90; H, 5.63; N, 23.01%. 
 
5-Hydrazono-5,6,7,8-tetrahydro-2H-pyrazolo[3,4-b]quinolin-3-ol (10c). Pale yellow crystals 
from ethanol, yield (1.47 g, 68%), mp 210-212 oC, IR (KBr) νmax cm
-1: 3543-3428 (OH, NH2, 
NH), 2986 (CH2), 1658 (exocyclic C=N), 1630 (C=C); 
1H NMR (DMSO-d6, 200 MHz): = 
1.35-1.68 (m, 2H, CH2), 2.60-2.76 (m, 4H, 2CH2), 4.86 (s, 2H, NH2), 6.86 (s, 1H, pyridine H-4), 
8.26 (s, 1H, D2O exchangeable, NH), 10.20 (s, 1H, D2O exchangeable, OH); 
13C NMR (DMSO-
d6, 75 MHz): 19.8, 29.9, 35.5 (3CH2), 119.8, 122.1, 124.7, 133.3  (pyrazole C-4, C-5, pyridine 
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C-3, C-4), 153.8, 158.9, 164.0 (3C=N). EIMS: m/z 217 [M]+ (32%); analysis calcd for 
C10H11N5O (217.23): C, 55.29; H, 5.10; N, 32.24%. Found: C, 55.42; H, 5.23; N, 32.38%. 
 
2-Phenyl-5-(2-phenylhydrazono)-5,6,7,8-tetrahydro-2H-pyrazolo[3,4-b]quinolin-3-ol (10d). 
Pale yellow crystals from ethanol, yield (2.85 g, 70%), mp 244-247 oC, IR (KBr) νmax cm
-1: 
3551-3426 (OH, NH), 2985 (CH2), 1656 (exocyclic C=N), 1626 (C=C); 
1H NMR (DMSO-d6, 
200 MHz): = 1.33-1.67 (m, 2H, CH2), 2.62-2.78 (m, 4H, 2CH2), 6.85 (s, 1H, pyridine H-4), 
7.29-7.40 (m, 10H, 2C6H5), 8.24 (s, 1H, D2O exchangeable, NH), 10.20 (s, 1H, D2O 
exchangeable, OH); 13C NMR (DMSO-d6, 75 MHz): 19.4, 29.7, 35.9 (3CH2), 119.5, 122.7, 
133.0, 124.3, 124.4, 125.9, 126.7, 128.0, 129.1, 130.2, 131.6, 133.8 (2C6H5, pyrazole C-4, C-5, 
pyridine C-3, C-4), 156.6, 158.7, 163.5 (3C=N). EIMS: m/z 369 [M]+ (26%); analysis calcd for 
C22H19N5O (369.42): C, 71.53; H, 5.18; N, 18.96%. Found: C, 71.38; H, 5.36; N, 19.19%. 
 
General procedure for the synthesis of the 5,6,7,8-tetrahydroisoxazolo[3,4-b]quinoline  
derivatives 13a,b 
To a solution either of compound 7a (1.88 g, 0.01 mol) or 7b (2.35 g, 0.01 mol) in 1,4-dioxane 
(40 mL) containing sodium acetate (1.0 g) hydroxylamine hydrochloride (0.69 g, 0.01 mol) was 
added. The reaction mixture was heated under reflux for 3 h then poured onto ice/water mixture 
and the formed solid product was collected by filtration. 
 
3-Amino-7,8-dihydroisoxazolo[3,4-b]quinolin-5(6H)-one oxime (13a). Pale yellow crystals from 
ethanol, yield (1.65 g, 76%), mp 287-289 oC, IR (KBr) νmax cm
-1: 3563-3423 (OH, NH2), 2988 
(CH2), 1656 (exocyclic C=N),  1632 (C=C); 
1H NMR (DMSO-d6, 200 MHz): = 1.31-1.68 (m, 
2H, CH2), 2.63-2.78 (m, 4H, 2CH2), 4.88 (s, 2H, D2O exchangeable, NH2), 6.84 (s, 1H, pyridine 
H-4), 10.26 (s, 1H, D2O exchangeable, OH); 
13C NMR (DMSO-d6, 75 MHz): 19.4, 29.7, 35.9 
(3CH2), 120.5, 124.9, 126.3, 130.5 (isoxazole C-4, C-5, pyridine C-3, C-4), 158.7, 159.3, 163.8 
(3C=N). EIMS: m/z 218 [M]+ (26%); analysis calcd for C10H10N4O2 (218.21): C, 55.04; H, 4.62; 
N, 25.68%. Found: C, 55.22; H, 4.80; N, 25.77%. 
 
3-Hydroxy-7,8-dihydroisoxazolo[3,4-b]quinolin-5(6H)-one oxime (13b). Pale yellow crystals 
from ethanol, yield (1.75 g, 80%), mp 231-235 oC,  IR (KBr) νmax cm
-1: 3572-3438 (2OH), 2989 
(CH2), 1654 (exocyclic C=N),  1630 (C=C); 
1H NMR (DMSO-d6, 200 MHz): = 1.33-1.69 (m, 
2H, CH2), 2.65-2.78 (m, 4H, 2CH2), 6.83 (s, 1H, pyridine H-4), 10.23, 10.25 (2s, 2H, D2O 
exchangeable, 2OH); 13C NMR (DMSO-d6, 75 MHz): 19.8, 29.4, 35.7 (3CH2), 120.5, 124.9, 
126.3, 130.5  (isoxazole C-4, C-5, pyridine C-3, C-4),  158.9, 159.6, 164.4 (3C=N). EIMS: m/z 
219 [M]+ (20%); analysis calcd for C10H9N3O3 (219.20): C, 54.79; H, 4.14; N, 19.17%. Found: 
C, 54.88; H, 4.07; N, 19.32%. 
 
General procedure for the synthesis of the 5,6-dihydrobenzo[b]thiophene derivatives 14a,b 
 
To a solution of cyclohexan-1,3-dione (11.2 g, 0.10 mol) in 1,4-dioxane (70 mL) containing 
triethylamine (2.0 mL) each of elemental sulfur (3.20 g, 0.10 mol) and either of malononitrile 
(6.60 g, 0.10 mol) or ethyl cyanoacetate (10.70 g, 0.10 mol) were added. The whole reaction 
mixture was heated under reflux for 1 h then left to cool. The formed solid product, in each case, 
was collected by filtration.  
 
2-Amino-7-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (14a). Orange crystals from 
ethanol, yield (1.26 g, 66%), mp 186-188 oC, IR (KBr) νmax cm
-1: 3480-3321 (NH2), 2986 (CH2), 
2221 (CN), 1688 (CO), 1630 (C=C); 1H NMR (DMSO-d6, 200 MHz): = 1.44-1.69 (m, 2H, 
CH2), 2.65-2.73 (m, 4H, 2CH2), 4.82 (s, 2H, D2O exchangeable, NH2);
 13C NMR (DMSO-d6, 75 
MHz): 17.2, 24.6, 32.6 (3CH2), 116.9 (CN), 125.8, 128.3, 136.7, 142.9 (thiophene C), 167.8 
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(CO).  EIMS: m/z 192 [M]+ (34%); analysis calcd for C9H8N2OS (192.24): C, 56.23; H, 4.19; N, 
14.57; S, 16.68%. Found: C, 56.42; H, 4.23; N, 14.80; S, 16.72%. 
 
Ethyl 2-amino-7-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (14b). Orange crystals 
from ethanol, yield (1.74 g, 73%), mp 105-107 oC,  IR (KBr) νmax cm
-1: 3484-3342 (NH2), 2988 
(CH2), 1693, 1689 (2CO), 1632 (C=C); 
1H NMR (DMSO-d6, 200 MHz): = 1.13 (t, 3H, J = 
7.22 Hz, CH3), 1.42-1.69 (m, 2H, CH2), 2.64-2.73 (m, 4H, 2CH2), 4.23 (q, 2H, J = 7.22 Hz, 
CH2), 4.84 (s, 2H, D2O exchangeable, NH2); 
13C NMR (DMSO-d6, 75 MHz): 16.8 
(OCH2CH3), 17.8, 24.2, 32.1 (3CH2), 56.3 (OCH2CH3), 126.3, 128.9, 134.8, 143.2  (thiophene 
C),  164.2, 168.3 (2CO). EIMS: m/z 239 [M]+ (26%); analysis calcd for C11H13NO3S (239.29): 
C, 55.21; H, 5.48; N, 5.85; S, 13.40%. Found: C, 55.39; H, 5.52; N, 6.18; S, 13.66%. 
 
General procedure for the synthesis of the 5,6-dihydrobenzo[b]thiophen-7(4H)-ylidene)-2-
cyanoacetohydrazide 16a,b 
 
Method (A). Equimolar amounts of either of compound 14a (1.92 g, 0.01 mol) or 14b (2.39 g, 
0.01 mol) and cyanoacetylhydrazine (1.0 g, 0.01 mol) in 1,4-dioxane (40 mL) was heated under 
reflux for 2 h then left to cool. The formed solid product, in each case was collected by 
filtration. 
 
Method (B). To a solution of compound 17 (1.93 g, 0.01 mol) in 1,4-dioxane (70 mL) containing 
triethylamine (2.0 mL) each of elemental sulfur (0.32 g, 0.01 mol) and either of malononitrile 
(6.60 g, 0.10 mol) or ethyl cyanoacetate (1.07 g, 0.01 mol) were added. The whole reaction 
mixture was heated under reflux for 1 h then left to cool. The formed solid product, in each case, 
was collected by filtration.  
 
N'-(2-Amino-3-cyano-5,6-dihydrobenzo[b]thiophen-7(4H)-ylidene)-2-cyanoacetohydrazide 
(16a). Orange crystals from ethanol, yield (1.85 g, 68%), mp 215-218 oC,  IR (KBr) νmax cm
-1: 
3489-3327 (NH2, NH), 2980 (CH2), 2260 (CN), 1688 (CO), 1630 (C=C); 
1H NMR (DMSO-d6, 
200 MHz): = 1.40-1.68 (m, 2H, CH2), 2.60-2.71 (m, 4H, 2CH2), 4.42 (s, 2H, CH2), 4.80 (s, 
2H, D2O exchangeable, NH2), 8.31 (s, 1H, D2O exchangeable, NH); 
13C NMR (DMSO-d6, 75 
MHz): 18.3, 24.6, 32.8 (3CH2), 58.8 (CH2), 116.6, 117.4 (2CN), 126.6, 128.7, 134.6, 143.8  
(thiophene C), 164.8 (CO), 172.3 (C=N). EIMS: m/z 273 [M]+ (18%); analysis calcd for 
C12H11N5OS (273.31): C, 52.73; H, 4.06; N, 25.62; S, 11.73%. Found: C, 52.49; H, 4.32; N, 
25.80; S, 11.84%. 
 
Ethyl 2-amino-7-(2-(2-cyanoacetyl)hydrazono)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-
carboxylate (16b). Orange crystals from ethanol, yield (2.62 g, 82%), mp 147-149 oC, IR (KBr) 
νmax cm
-1: 3459-3342 (NH2, NH), 2983 (CH2), 1689, 1686 (2CO), 1654 (exocyclic C=N), 1632 
(C=C); 1H NMR (DMSO-d6, 200 MHz): = 1.13 (t, 3H, J = 7.04 Hz, CH3), 1.42-1.69 (m, 2H, 
CH2), 2.63-2.70 (m, 4H, 2CH2), 4.22 (q, 2H, J = 7.04 Hz, CH2), 4.40 (s, 2H, CH2), 4.81 (s, 2H, 
D2O exchangeable, NH2), 8.32 (s, 1H, D2O exchangeable, NH); 
13C NMR (DMSO-d6, 75 
MHz): 16.9 (OCH2CH3), 18.4, 24.2, 32.9 (3CH2), 56.2 (OCH2CH3), 116.4 (CN), 126.4, 128.3, 
134.8, 143.8  (thiophene C), 164.9, 166.5 (2CO). EIMS:  m/z 320  [M]+ (25%); analysis calcd 
for C14H16N4O3S (320.37): C, 52.49; H, 5.03; N, 17.49; S, 10.01%. Found: C, 52.53; H, 4.92; N, 
17.28; S, 10.32%. 
 
2-Cyano-N'-(3-oxocyclohexylidene)acetohydrazide (17). To a solution of cyclohexan-1,3-dione 
(1.12 g, 0.01 mol) in 1,4-dioxane (40 mL) cyanoacetylhydrazine (1.0 g, 0.01 mol) was added. 
The reaction mixture was heated under reflux for 2 h then left to cool. The formed solid product, 
in each case was collected by filtration. White crystals from ethanol, yield (1.5 g, 78%), mp 
220-222 oC, IR (KBr) νmax cm
-1: 3473-3330 (NH), 2984 (CH2), 1691, 1687 (2CO), 1650 
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(exocyclic C=N), 1630 (C=C); 1H NMR (DMSO-d6, 200 MHz): = 1.43-1.69 (m, 2H, CH2), 
2.62-2.73 (m, 4H, 2CH2), 2.93 (s, 2H, CH2), 4.43 (s, 2H, CH2), 8.29 (s, 1H, D2O exchangeable, 
NH); 13C NMR (DMSO-d6, 75 MHz): 18.5, 26.3, 34.2, 38.4 (4CH2), 64.2  (CH2), 117.2 (CN), 
126.4, 128.3, 134.8, 143.8 (thiophene C), 164.6, 167.2 (2CO), 172.4 (C=N). EIMS: m/z 193  
[M]+ (32%); analysis calcd for C9H11N3O2 (193.20): C, 55.95; H, 5.74; N, 21.75%. Found: C, 
55.69; H, 5.92; N, 21.80%. 
 
General procedure for the synthesis of the 5,6-dihydro-4H-thieno[3,2-h]chromene derivatives 
18a-f 
 
To a solution of either of compound 14a (2.86 g, 0.01 mol), 14b (3.20 g, 0.01 mol) in 1,4-
dioxane (40 mL) containing triethylamine (0.50 mL) any of benzaldehyde (1.06 g, 0.01 mol), 4-
chlorobenzaldehyde (1.40 g, 0.01 mol) or 4-methoxybenzaldehyde (1.83 g, 0.01 mol) and 
malononitrile (0.66 g, 0.01 mol) were added. The whole reaction mixture was heated under 
reflux for 3 h then left to cool and the formed solid product, in each case, was collected by 
filtration.  
 
2,8-Diamino-4-phenyl-5,6-dihydro-4H-thieno[3,2-h]chromene-3,7-dicarbonitrile (18a). Yellow 
crystals from 1,4-dioxane, yield (2.42 g, 70%), mp 130-132 oC, IR (KBr) νmax cm
-1: 3489-3341 
(NH2), 2980 (CH2), 2223, 2220 (2CN), 1626 (C=C); 
1H NMR (DMSO-d6, 200 MHz): = 2.62-
2.78 (2t, 4H, J = 6.87 Hz, 2CH2), 4.47, 4.80 (2s, 4H, D2O exchangeable, 2NH2), 6.09 (s, 1H, 
pyran H-4), 7.28-7.41 (m, 5H, C6H5); 
13C NMR (DMSO-d6, 75 MHz): 44.6, 50.3 (2CH2), 60.8 
(pyran C-4), 116.8, 117.2 (2CN), 120.3, 122.1, 125.8, 126.4, 128.9, 129.2, 129.6, 132.8, 133.1, 
136.5, 143.8, 145.7, 150.6  (C6H5, pyran, thiophene C). EIMS: m/z 346 [M]
+ (28%); analysis 
calcd for C19H14N4OS (346.41): C, 65.88; H, 4.07; N, 16.17; S, 9.26%. Found: C, 65.69; H, 
3.90; N, 16.08; S, 9.42%. 
 
2,8-Diamino-4-(4-chlorophenyl)-5,6-dihydro-4H-thieno[3,2-h]chromene-3,7-dicarbonitrile 
(18b). Yellow crystals from 1,4-dioxane, yield (2.74 g, 72%), mp 102-104 oC,  IR (KBr) νmax 
cm-1: 3465-3328 (NH2), 2983 (CH2), 2223, 2220 (2CN), 1628 (C=C); 
1H NMR (DMSO-d6, 200 
MHz): = 2.64-2.79 (2t, 4H, 2CH2), 4.48, 4.82 (2s, 4H, D2O exchangeable, 2NH2), 6.09 (s, 1H, 
pyran H-4), 7.24-7.47 (m, 4H, C6H4); 
13C NMR (DMSO-d6, 75 MHz): 44.9, 50.1 (2CH2), 60.6 
(pyran C-4), 116.7, 117.5 (2CN), 120.6, 122.3, 125.4, 126.8, 128.2, 129.0, 131.2, 132.6, 133.6, 
143.8, 145.5, 150.8 (C6H4, pyran, thiophene C). EIMS: m/z 380 [M]
+ (46%); analysis calcd for 
C19H13ClN4OS (380.85): C, 59.92; H, 3.44; N, 14.71; S, 8.42%. Found: C, 60.16; H, 3.52; N, 
14.93; S, 8.66%. 
 
2,8-Diamino-4-(4-methoxyphenyl)-5,6-dihydro-4H-thieno[3,2-h]chromene-3,7-dicarbonitrile 
(18c). Yellow crystals from 1,4-dioxane, yield (2.25 g, 60%), mp 182-185 oC,  IR (KBr) νmax 
cm-1: 3485-3341 (NH2), 2980, 2873 (CH3, CH2), 2224, 2220 (2CN), 1629 (C=C); 
1H NMR 
(DMSO-d6, 200 MHz): = 2.62-2.75 (2t, 4H, 2CH2), 3.69 (s, 3H, OCH3), 4.42, 4.86 (2s, 4H, 
2NH2), 6.07 (s, 1H, pyran H-4), 7.26-7.49 (m, 4H, C6H4); 
13C NMR (DMSO-d6, 75 MHz): 
44.8, 50.6 (2CH2), 53.6 (OCH3), 60.3 (pyran C-4), 116.9, 117.0 (2CN), 121.8, 122.6, 125.4, 
127.3, 128.0, 130.4, 132.5, 133.3, 136.6, 143.7, 145.3, 150.2 (C6H5, pyran, thiophene C).  
EIMS: m/z 376 [M]+ (26%); analysis calcd for C20H16N4O2S (376.43): C, 63.81; H, 4.28; N, 
14.88; S, 8.52%. Found: C, 64.01; H, 4.37; N, 14.59; S, 8.71%. 
 
Ethyl 2,8-diamino-3-cyano-4-phenyl-5,6-dihydro-4H-thieno[3,2-h]chromene-7-carboxylate 
(18d). Pale yellow crystals from 1,4-dioxane, yield (2.67 g, 68%), mp 194-196 oC,  IR (KBr) 
νmax cm
-1: 3480-3358 (NH2), 2986, 2878 (CH3, CH2), 2220 (CN), 1688 (CO), 1627 (C=C); 1H 
NMR (DMSO-d6, 200 MHz): = 1.14 (t, 3H, J = 6.78 Hz, CH3), 2.60-2.78 (2t, 4H, 2CH2), 4.22 
Rafat Milad Mohareb et al. 
Bull. Chem. Soc. Ethiop. 2018, 32(2) 
304
(q, 2H, J = 6.78 Hz, CH2), 4.47, 4.88 (2s, 4H, 2NH2), 6.079 (s, 1H, pyran H-4), 7.29-7.42 (m, 
5H, C6H5);
 13C NMR (DMSO-d6, 75 MHz): 16.8 (OCH2CH3), 44.5, 50.8 (2CH2), 52.8 
(OCH2CH3), 60.3 (pyran C-4), 116.6 (CN), 120.3, 122.5, 125.2, 126.7, 128.3, 130.6, 131.3, 
134.9, 135.2, 143.9, 147.8, 150.0 (C6H5, pyran, thiophene C), 164.3 (CO). EIMS: m/z 393 [M]
+  
(38%); analysis calcd for C21H19N3O3S (393.46): C, 64.10; H, 4.87; N, 10.68; S, 8.15%. Found: 
C, 64.26; H, 4.69; N, 10.49; S, 8.65%. 
 
Ethyl 2,8-diamino-4-(4-chlorophenyl)-3-cyano-5,6-dihydro-4H-thieno[3,2-h]chromene-7-
carboxylate (18e). Yellow crystals from 1,4-dioxane, yield (3.12 g, 73%), mp 190-193 oC, IR 
(KBr) νmax cm
-1: 3489-3342 (NH2), 2986, 2875 (CH3, CH2), 2222 (CN), 1680 (CO), 1625 
(C=C); 1H NMR (DMSO-d6, 200 MHz): = 
1H NMR (DMSO-d6, 200 MHz): = 1.14 (t, 3H, J 
= 6.99 Hz, CH3), 2.62-2.79 (2t, 4H, 2CH2), 4.24 (q, 2H, J = 6.99 Hz, CH2), 4.47, 4.89 (2s, 4H, 
2NH2), 6.08 (s, 1H, pyran H-4), 7.24-7.49 (m, 4H, C6H4); 
13C NMR (DMSO-d6, 75 MHz): 
16.9 (OCH2CH3), 44.5, 50.6 (2CH2), 52.6 (OCH2CH3), 60.8 (pyran C-4), 116.9 (CN), 120.6, 
122.3, 125.8, 126.9, 128.3, 130.8, 132.6, 134.6, 135.8, 146.1, 147.5, 150.3 (C6H5, pyran, 
thiophene C), 164.2 (CO). EIMS: m/z 427 [M]+ (30%); analysis calcd for C21H18ClN3O3S 
(427.90): C, 58.94; H, 4.24; N, 9.82; S, 7.49%. Found: C, 58.83; H, 4.53; N, 10.05; S, 7.66%. 
 
Ethyl 2,8-diamino-3-cyano-4-(4-methoxyphenyl)-5,6-dihydro-4H-thieno[3,2-h]chromene-7-
carboxylate (18f). Yellow crystals from 1,4-dioxane, yield (3.30 g, 78%), mp 92-94 oC, IR 
(KBr) νmax cm
-1: 3477-3328 (NH2), 2984, 2878 (CH3, CH2), 2220 (CN), 1686 (CO), 1627 
(C=C); 1H NMR (DMSO-d6, 200 MHz): = 
1H NMR (DMSO-d6, 200 MHz): = 1.12 (t, 3H, J 
= 7.31 Hz, CH3), 2.60-2.78 (2t, 4H, 2CH2), 3.68 (s, 3H, OCH3), 4.23 (q, 2H, J = 7.31 Hz, CH2), 
4.47, 4.87 (2s, 4H, 2NH2), 6.06 (s, 1H, pyran H-4), 7.22-7.48 (m, 4H, C6H4); 
13C NMR (DMSO-
d6, 75 MHz): 16.3 (OCH2CH3), 44.8, 50.6 (2CH2), 52.7 (OCH2CH3), 53.4 (OCH3), 60.8 (pyran 
C-4), 116.6 (CN), 121.2, 122.6, 125.4, 126.2, 127.8, 129.4, 132.8, 134.6, 135.8, 146.4, 147.7, 
150.6 (C6H5, pyran, thiophene C), 164.8 (CO). EIMS: m/z 423 [M]
+  (26%); analysis calcd for 
C22H21N3O4S (423.48): C, 62.40; H, 5.00; N, 9.92; S, 7.57%. Found: C, 62.59; H, 4.94; N, 
10.24; S, 7.72%. 
 
N-(2-Amino-3,7-dicyano-4-phenyl-5,6-dihydro-4H-thieno[3,2-h]chromen-8-yl)-2-cyanoacet- 
amide (19). A solution of equimolecular amounts of compound 18a (3.46 g, 0.01 mol) and ethyl 
cyanoacetate (1.07 g, 0.01 mol) in dimethylformamide (30 mL) was heated under reflux for 3 h. 
The solid product, so formed, upon pouring onto ice/water mixture was collected by filtration. 
Pale yellow crystals from 1,4-dioxane, yield (2.72 g, 66%), mp 181-183 oC, IR (KBr) νmax cm
-1: 
3495-3345 (NH2), 2986 (CH2), 2223-2220 (3CN), 1687 (C=O), 1627 (C=C); 
1H NMR (DMSO-
d6, 200 MHz): = 
1H NMR (DMSO-d6, 200 MHz): = 2.64-2.85 (2t, 4H, 2CH2), 3.93 (s, 2H, 
CH2), 4.89 (s, 2H, D2O exchangeable, NH2), 6.08 (s, 1H, pyran H-4), 7.28-7.38 (m, 5H, C6H5), 
8.30 (s, 1H, D2O exchangeable, NH); 
13C NMR (DMSO-d6, 75 MHz): 44.3, 50.9 (2CH2), 57.6 
(CH2), 60.4 (pyran C-4), 116.8, 117.1, 117.6 (3CN), 120.8, 121.9, 123.6, 124.9, 126.2, 129.4, 
132.8, 134.6, 138.2, 146.4, 148.2, 149.8 (C6H5, pyran, thiophene C), 168.3 (CO). EIMS: m/z 
413 [M]+ (18%); analysis calcd for C22H15N5O2S (413.45): C, 63.91; H, 3.66; N, 16.94; S, 
7.76%. Found: C, 64.25; H, 3.80; N, 17.28; S, 7.82%. 
General procedure for the synthesis of the dihydrobenzo[b]thiophen-7(4H)-ylidene)-thiophene-
2-carbohydrazide derivatives 20a,b 
To a solution of compound 16a (2.73 g, 0.01 mol) in 1,4-dioxane (40 mL) containing 
triethylamine (2.0 mL) each of elemental sulfur (0.32 g, 0.01 mol) and either of malononitrile 
(0.66 g, 0.01 mol) or ethyl cyanoacetate (1.07 g, 0.10 mol) were added. The whole reaction 
mixture was heated under reflux for 2 h then left to cool. The formed solid product, in each case, 
was collected by filtration.  
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3,5-Diamino-N'-(2-amino-3-cyano-5,6-dihydrobenzo[b]thiophen-7(4H)-ylidene)-4-cyanothio- 
phene-2-carbohydrazide (20a). Orange crystals from acetic acid, yield (2.71 g, 73%), mp 182-
184 oC,  IR (KBr) νmax cm
-1: 3485-3371 (NH2, NH), 2988 (CH2), 2226, 2220 (2CN), 1688 
(C=O), 1629 (C=C); 1H NMR (DMSO-d6, 200 MHz): = 
1H NMR (DMSO-d6, 200 MHz): = 
1.48 (m, 4H, 2CH2), 2.62-2.87 (m, 2H, CH2), 4.59, 4.89, 5.11 (3s, 6H, D2O exchangeable, 
3NH2), 8.33 (s, 1H, D2O exchangeable, NH); 
13C NMR (DMSO-d6, 75 MHz): 18.8, 24.8, 35.2 
(2CH2), 116.6, 117.2 (2CN), 120.4, 122.9, 126.0, 128.2, 130.4, 136.4, 144.0, 148.2  (two 
thiophene C), 165.8 (CO). EIMS: m/z 371 [M]+ (20%); analysis calcd for C15H13N7OS2 
(371.44): C, 48.50; H, 3.53; N, 26.40; S, 17.27%. Found: C, 48.59; H, 3.38; N, 26.49; S, 
16.91%. 
Ethyl 2,4-diamino-5-(2-(2-amino-3-cyano-5,6-dihydrobenzo[b]thiophen-7(4H)-ylidene)-
hydrazinecarbonyl)thiophene-3-carboxylate (20b). Orange crystals from acetic acid, yield (2.92 
g, 70%), mp 196-199 oC,  IR (KBr) νmax cm
-1: 3489-3369 (NH2, NH), 2987 (CH2), 2220 (CN), 
1687 (C=O), 1628 (C=C); 1H NMR (DMSO-d6, 200 MHz): = 
1H NMR (DMSO-d6, 200 
MHz): = 1.14 (t, 3H, J = 6.55 Hz, ester CH3), 1.49 (m, 4H, 2CH2), 2.60-2.87 (m, 2H, CH2), 
4.23 (q, 2H, J = 6.55 Hz, ester CH2), 4.63, 4.85, 5.13 (3s, 6H, D2O exchangeable, 3NH2), 8.32 
(s, 1H, D2O exchangeable, NH); 
13C NMR (DMSO-d6, 75 MHz): 16.6 (OCH2CH3), 18.6, 24.8, 
32.9 (2CH2), 52.6 (OCH2CH3), 116.8 (CN), 126.2, 128.5, 132.8, 134.6, 136.6, 146.4, 147.3, 
149.4  (thiophene C), 164.2, 168.8 (2CO). EIMS: m/z 418 [M]+ (37%); analysis calcd for 
C17H18N6O3S2 (418.49): C, 48.79; H, 4.34; N, 20.08; S, 15.32%. Found: C, 48.64; H, 4.59; N, 
20.16; S, 15.52%. 
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